Search clinical trials for: E2007 (perampanel)

Total 169 results

Eisai Inc.

Completed

Dose-Tolerability Titration Study to Evaluate The Efficacy And Safety Of Perampanel (E2007) In Patients With Post-Herpetic Neuralgia (PHN)

Neuralgia

United States, Canada
Eisai Inc.

Completed

Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

Partial Onset Seizures | Primary Generalized Tonic-Clonic Seizures | Secondarily Generalized Seizures

United States
Eisai Inc.

Completed

Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Refractory Partial Seizures

United States, Chile, Brazil, Canada, Mexico, Argentina
Eisai Inc.

Completed

To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Refractory Partial Seizures

United States, France, Germany, Italy, United Kingdom, Belgium, Israel, South Africa, Finland, Russian Federation, Austria, Netherlands, Sweden, India
Eisai Inc.

Completed

Study to Evaluate Bioavailability of a Single 12 mg Dose of Perampanel for Three Intravenous Infusion Durations Relative to a Single 12 mg Perampanel Oral Tablet in Healthy Subjects

Healthy Participants

United States
Eisai Inc.

Completed

Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)

Neuralgia

United States
Eisai Inc.

Terminated

Long-Term Safety, Tolerability and Efficacy in Perampanel Treated Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease
Eisai Inc.

Completed

A Efficacy and Safety Study of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures

Seizure Disorder Generalized Tonic Clonic
Eisai Inc.

Completed

Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy

Epilepsy

United States, Latvia
Eisai Korea Inc.

Completed

Trial Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Participants With Partial Onset Seizures With or Without Secondary Generalization

Epilepsy

Korea, Republic of
Eisai Co., Ltd.

Completed

Bioequivalence Study Between a 4-mg Dose of Fine Granules of Perampanel and a 4-mg Tablet of Perampanel in Healthy Japanese Subjects

Healthy Participants

Japan
Eisai Co., Ltd.

Completed

Pharmacokinetic Study of Perampanel in Chinese Healthy Subjects

Healthy Subjects

China
Eisai Inc.

Terminated

Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome

Lennox-Gastaut Syndrome (LGS)

Korea, Republic of, United States, Australia, Belgium, Japan, Czechia, India
Eisai Co., Ltd.

Completed

A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures

Partial-onset Seizures

Korea, Republic of, Japan, Australia, China, Malaysia, Taiwan, Thailand
Eisai Pharmaceuticals India Pvt. Ltd

Completed

A Study to Assess Safety and Efficacy of Perampanel in Indian Participants as an Adjunctive Treatment in Partial Onset Seizures With or Without Secondary Generalized Seizures in Participants With Epilepsy Aged 12 Years or Older

Epilepsy | Partial Onset Seizures

India
Eisai Limited

Completed

A Study of Perampanel as Add-on Therapy in Adult and Adolescent Participants With Focal Seizures

Partial Seizures
Eisai Co., Ltd.

Completed

An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects

Epilepsy

Japan
Eisai Korea Inc.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizures With or Without Focal to Bilateral Tonic-clonic Seizures

Epilepsy

Korea, Republic of
Eisai GmbH

Completed

A Study to Evaluate the Effectiveness of Perampanel as Only Add-on Treatment in Participants With Primary or Secondarily Generalized Tonic-clonic Seizures

Seizures

Germany
Eisai Inc.

Available

An Extended Access Program (EAP) for Perampanel

Lennox Gastaut Syndrome | Primary Generalized Tonic-Clonic or Partial Onset Seizures

Belgium, Chile, Estonia, Hungary, Latvia, Lithuania, Poland, Spain
Eisai Inc.

Completed

Evaluating Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Refractory Partial Seizures

Hong Kong, Italy, Australia, Spain, Portugal, Taiwan, India, Thailand, Hungary, Poland, Bulgaria, Serbia, Russian Federation, Korea, Republic of, Ukraine, Romania, Latvia, Lithuania, Germany, Estonia, Czech Republic, Philippines, Ma...
Eisai Inc.

Completed

E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

Epilepsy

United States
Eisai Inc.

Recruiting

A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

Partial-onset Seizures | Pediatric Epileptic Syndrome

United States, Spain, France, Belgium, Czechia, Denmark, Germany
Eisai Inc.
Eisai Limited

Completed

An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy

Diabetic Neuropathy

United States
Eisai Inc.

No longer available

An Extended Access Program for Perampanel

Partial Onset Seizures

Italy, Spain, Belgium, Israel, Poland, Taiwan, Czechia, Finland, Thailand, Malaysia, Argentina, Chile, Canada, Hungary, Australia, Lithuania, Latvia, Estonia, Netherlands, Greece, Hong Kong
Eisai Co., Ltd.

Completed

A Study of Intravenous Perampanel in Japanese Participants With Epilepsy

Epilepsy | Seizures

Japan
Eisai Co., Ltd.

Completed

A Study to Evaluate the Safety and Efficacy of Fycompa® (Perampanel) as Add-on Therapy in Participants With Epilepsy

Epilepsy | Partial-onset Seizures
Eisai Co., Ltd.

Completed

A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs)

Refractory Partial Seizures

Japan
Eisai Co., Ltd.

Completed

Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Participants With Partial Onset Seizures (Including Secondarily Generalized Seizures (FREEDOM Study)

Partial Onset Seizures

Japan, Korea, Republic of
Dana-Farber Cancer Institute
National Cancer Institute (NCI); Eisai Inc.

Completed

Effect of Perampanel on Peritumoral Hyperexcitability in HGG

Seizures | Surgery | Glioma, Malignant

United States
Eisai Inc.

Completed

A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations

Parkinson's Disease

United States
Eisai Inc.

Terminated

A Study of E2007 In Patients With Parkinson's Disease

Parkinson's Disease

United States
Eisai Inc.

Completed

Efficacy and Safety Study of E2007 in Migraine Prophylaxis

Migraine Prophylaxis

United States
Kimford Jay Meador
Eisai Inc.

Recruiting

Perampanel Titration and Cognitive Effects

Epilepsy

United States
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy

Malignant Glioma | WHO Grade 3 Glioma | Intractable Epilepsy | Seizure Disorder | WHO Grade 2 Glioma

United States
Weill Medical College of Cornell University
Eisai Inc.

Completed

Effects of Perampanel on Neurophysiology Test Perimeters

Healthy

United States
Eisai Co., Ltd.

Completed

Safety and Pharmacokinetics Study of E2007 to Treat Partial and Generalised Seizures in People With Epilepsy

Epilepsy

Germany
National Taiwan University Hospital

Completed

The Efficacy of Fycompa (Perampanel) in Children With Epilepsy

Neurologic Disorder

Taiwan
University Health Network, Toronto
Dystonia Study Group

Completed

Safety and Tolerability of Perampanel in Cervical Dystonia (SAFE-PER-CD)

Cervical Dystonia

United States, Canada
Hospices Civils de Lyon

Completed

Retrospective Evaluation of Perampanel in a French Neurology and Epileptology Department (Hospices Civil de Lyon) (PERLYON)

Refractory Epilepsy

France
Eisai Inc.

Completed

4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures

Epilepsy

Belgium, France, United States, Czech Republic, Estonia, Latvia, Spain, United Kingdom, Lithuania, Germany, Australia, Finland, Netherlands, Sweden
Eisai Inc.

Completed

Demonstrate Bioequivalence Between 3 x 2-mg Tablets of Perampanel and a Single 6-mg Tablet of Perampanel in Healthy Subjects

Healthy

United States
Eisai Co., Ltd.
Eisai Limited

Completed

Exploring the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients With Refractory Partial Seizures

Epilepsy

Latvia
Eisai Inc.

Completed

Study to Assess the Safety, Tolerability, Pharmacokinetics of E2027 in Healthy Adult and Elderly Subjects, and the Pharmacodynamics in Healthy Adult Subjects

Healthy Participants

United States
Eisai Limited

Completed

A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy

Idiopathic Generalized Epilepsy | Partial Onset Seizures | Generalised Tonic-Clonic Seizures

France, Spain, Italy, Denmark, Germany, Portugal, Russian Federation
Eisai Inc.

Withdrawn

To Evaluate the Effect of Perampanel on Objective and Subjective Sleep in Subjects With Insomnia and Partial Onset Seizures

Epilepsy, Partial
Eisai Inc.

Completed

A Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Japanese and White Subjects

Healthy Volunteers

United States
Eisai Inc.

Completed

A Global, Postmarketing Observational Safety Study to Evaluate the Safety and Tolerability of Fycompa (Perampanel) as Add-on Therapy in Epilepsy Patients Aged Greater Than or Equal to 12 Years

Epilepsy

Belgium, Israel, United Kingdom, Austria, Sweden, Czechia
Eisai Co., Ltd.

Completed

A Multiple Dose Pharmacokinetic Study of Perampanel in Korean Healthy Subjects

Healthy

Korea, Republic of
Eisai Inc.

Completed

A Study to Demonstrate Bioequivalence Between 6 x 2 mg Tablets of Perampanel and a Single 12 mg Tablet of Perampanel in Healthy Subjects

Partial Onset Epilepsy

United Kingdom

3

Subscribe